Trial reportJournal of neurology2006
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.
Trial report in Journal of neurology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 6 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.The pharmacogenomics journal · 2017Pooled it
- Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Guideline
- Pooled it
- Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Guideline
- Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.Journal of neurology · 2008Guideline
- [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].Der Nervenarzt · 2006Guideline
- Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.BMC neurology · 2016Trial
- Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study.PloS one · 2016Trial
- Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.BMC neurology · 2014Trial
- Correlation Is Not Prediction: Reassessing Predictive MRI Evidence in Guidelines for Persons With Relapsing-Remitting Multiple Sclerosis.Journal of central nervous system disease · 2026Article
- Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects.Journal of personalized medicine · 2022Review
- Predictive value of number and volume of demyelinating plaques in treatment response in patients with multiple sclerosis treated with INF-B.American journal of neurodegenerative disease · 2022Article
- Diagnosis and management of multiple sclerosis: MRI in clinical practice.Journal of neurology · 2020Article
- Predicting the profile of increasing disability in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Article
- Review
- Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.AJNR. American journal of neuroradiology · 2017Review
- MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.Therapeutic advances in neurological disorders · 2017Review
- Defining Disease Activity and Response to Therapy in MS.Current treatment options in neurology · 2017Review
- Aggressive multiple sclerosis: proposed definition and treatment algorithm.Nature reviews. Neurology · 2015Review
- Identifying responders and nonresponders to interferon therapy in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to identify clinical, magnetic resonance imaging (MRI) and biological markers predictive of long-term clinical response to interferon beta (IFN beta) therapy in patients with relapsing-remitting multiple sclerosis (RRMS).
methodsSixty-eight patients treated with IFN beta were followed over a 6-year period. Relapse rate and disability progression were evaluated throughout the study. We considered suboptimal clinical response to be either the presence of sustained disability progression, or more than two relapses. Baseline and 12-month demographic, clinical and MRI findings, as well as the development of neutralizing antibodies (NAbs) against IFN beta during the first year of therapy were analyzed as predictors of long-term clinical outcome.
results"Black holes" on MRI were the best baseline predictor of disability progression (odds ratio [OR] 6.8; p < 0.001). At 1 year, both male gender (OR 4.9; p = 0.009) and NAbs (OR 7.3; p = 0.003) were independently associated with a high risk of developing subsequent disability. The presence of gadolinium enhancement, both at baseline (OR 4.7; p = 0.005) and on the 1-year MRI scan (OR 7.9; p = 0.002), was the unique variable associated with the number of relapses over the study period.
conclusionsVariables assessable within the first year of treatment significantly influence relapse rate and disability progression in patients with RRMS treated with IFN beta. These findings may help clinicians to make decisions regarding therapy regimen over time, and highlight the need for a prognostic algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.